Inconsistent quality of products purchased online, and confusion over cannabis itself, could be putting patients at risk, a group of UK MPs were told during presentations on medical cannabis and related issues
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets. Most content is available to subscribers only.